终末期肝脏疾病细胞治疗的研究进展

doi:10.3969/j.issn.1004-616x.2023.02.011

摘要/Abstract

摘要： 终末期肝病包括肝衰竭和失代偿期肝硬化等类型，临床表现为肝细胞功能异常而导致肝脏蛋白合成、代谢等功能丧失。在我国，每年约有30万人死于终末期肝脏疾病。原位肝移植是治疗终末期肝病最为直接且有效的方式，但由于供肝资源短缺、免疫排斥和手术费昂贵等问题的存在，极大限制了其在临床上的广泛应用。细胞治疗是潜在的能够替代肝移植的唯一有希望的治疗方法，其主要是通过将体外获得的细胞移植入受体肝脏中，植入肝脏的外源细胞进行增殖并逐渐再殖受损肝脏从而实现损伤肝脏功能的修复。本文拟对有望成为细胞治疗的供体细胞如原代或诱导型肝细胞、肝脏干/前体细胞、间充质干细胞、肝脏类器官等细胞类型在动物实验和临床应用中取得的进展进行概述，为其应用于终末期肝脏疾病的临床治疗提供理论基础。

关键词: 终末期肝病, 细胞治疗, 肝细胞, 成体干细胞, 肝脏类器官

中图分类号:

R575.3

彭蕾, 王敏君. 终末期肝脏疾病细胞治疗的研究进展[J]. 癌变·畸变·突变, 2023, 35(2): 144-147.

参考文献

[1] IANSANTE V, MITRY R R, FILIPPI C, et al. Human hepatocyte transplantation for liver disease: current status and future perspectives [J]. Pediatr Res, 2018, 83(1/2): 232-240.
[2] HUEBERT R C, RAKELA J. Cellular therapy for liver disease[J]. Mayo Clin Proc, 2014, 89(3): 414-424.
[3] WANG F, ZHOU L, MA X, et al. Monitoring of intrasplenic hepatocyte transplantation for acute-on-chronic liver failure: a prospective fiveyear follow-up study[J]. Transplant Proc, 2014, 46(1): 192-198.
[4] FU G B, HUANG W J, ZENG M, et al. Expansion and differentiation of human hepatocyte-derived liver progenitor-like cells and their use for the study of hepatotropic pathogens[J]. Cell Res, 2019, 29(1): 8-22.
[5] PENG W C, LOGAN C Y, FISH M, et al. Inflammatory cytokine TNFα promotes the long-term expansion of primary hepatocytes in 3D culture [J]. Cell, 2018, 175(6): 1607-1619.e15.
[6] ZHANG K, ZHANG L D, LIU W M, et al. In vitro expansion of primary human hepatocytes with efficient liver repopulation capacity[J]. Cell Stem Cell, 2018, 23(6): 806-819.e4.
[7] KIM Y, KANG K, LEE S B, et al. Small molecule-mediated reprogramming of human hepatocytes into bipotent progenitor cells[J]. J Hepatol, 2019, 70(1): 97-107.
[8] FENG S S, WU J Y, QIU W L, et al. Large-scale generation of functional and transplantable hepatocytes and cholangiocytes from human endoderm stem cells[J]. Cell Rep, 2020, 33(10): 108455.
[9] CHEN S T, WANG J L, REN H Z, et al. Hepatic spheroids derived from human induced pluripotent stem cells in bio-artificial liver rescue porcine acute liver failure[J]. Cell Res, 2020, 30(1): 95-97.
[10] KO S, RUSSELL J O, MOLINA L M, et al. Liver progenitors and adult cell plasticity in hepatic injury and repair: knowns and unknowns[J]. Annu Rev Pathol, 2020, 15: 23-50.
[11] IRUDAYASWAMY A, MUTHIAH M, ZHOU L, et al. Long-term fate of human fetal liver progenitor cells transplanted in injured mouse livers [J]. Stem Cells, 2018, 36(1): 103-113.
[12] PIETROSI G, VIZZINI G, GERLACH J, et al. Phases I-II matched case-control study of human fetal liver cell transplantation for treatment of chronic liver disease[J]. Cell Transplant, 2015, 24(8): 1627-1638.
[13] HUCH M, DORRELL C, BOJ S F, et al. In vitro expansion of single Lgr5+ liver stem cells induced by Wnt-driven regeneration[J]. Nature, 2013, 494(7436): 247-250.
[14] HUCH M, GEHART H, VAN BOXTEL R, et al. Long-term culture of genome-stable bipotent stem cells from adult human liver[J]. Cell, 2015, 160(1/2): 299-312.
[15] LU W Y, BIRD T G, BOULTER L, et al. Hepatic progenitor cells of biliary origin with liver repopulation capacity[J]. Nat Cell Biol, 2015, 17(8): 971-983.
[16] KATSUDA T, KAWAMATA M, HAGIWARA K, et al. Conversion of terminally committed hepatocytes to culturable bipotent progenitor cells with regenerative capacity[J]. Cell Stem Cell, 2017, 20(1): 41-55.
[17] YU B, HE Z Y, YOU P, et al. Reprogramming fibroblasts into bipotential hepatic stem cells by defined factors[J]. Cell Stem Cell, 2013, 13(3): 328-340.
[18] HUANG W J, ZHOU X, FU G B, et al. The combined induction of liver progenitor cells and the suppression of stellate cells by small molecules reverts chronic hepatic dysfunction[J]. Theranostics, 2021, 11(11): 5539-5552.
[19] LIU W H, SONG F Q, REN L N, et al. The multiple functional roles of mesenchymal stem cells in participating in treating liver diseases[J]. J Cell Mol Med, 2015, 19(3): 511-520.
[20] HARN H J, LIN S Z, HUNG S H, et al. Adipose-derived stem cells can abrogate chemical-induced liver fibrosis and facilitate recovery of liver function[J]. Cell Transplant, 2012, 21(12): 2753-2764.
[21] LIU S R, GUO R H, HOU X L, et al. Adipose-tissue derived porcine mesenchymal stem cells efficiently ameliorate CCl₄-induced acute liver failure in mice[J]. Cytotechnology, 2020, 72(3): 327-341.
[22] SASAJIMA H, MIYAGI S, KAKIZAKI Y, et al. Cytoprotective effects of mesenchymal stem cells during liver transplantation from donors after cardiac death in rats[J]. Transplant Proc, 2018, 50(9): 2815-2820.
[23] SHI D Y, ZHANG J N, ZHOU Q, et al. Quantitative evaluation of human bone mesenchymal stem cells rescuing fulminant hepatic failure in pigs[J]. Gut, 2017, 66(5): 955-964.
[24] LI Y H, XU Y, WU H M, et al. Umbilical cord-derived mesenchymal stem cell transplantation in hepatitis B virus related acute-on-chronic liver failure treated with plasma exchange and entecavir: a 24-month prospective study[J]. Stem Cell Rev and Rep, 2016, 12(6): 645-653.
[25] KIM Y H, CHO K A, PARK M, et al. Conditioned medium from tonsilderived mesenchymal stem cells relieves CCl₄-induced liver fibrosis in mice[J]. Tissue Eng Regen Med, 2019, 16(1): 51-58.
[26] TAKEBE T, SEKINE K, ENOMURA M, et al. Vascularized and functional human liver from an iPSC-derived organ bud transplant[J]. Nature, 2013, 499(7459): 481-484.
[27] TAKEBE T, SEKINE K, KIMURA M, et al. Massive and reproducible production of liver buds entirely from human pluripotent stem cells[J]. Cell Rep, 2017, 21(10): 2661-2670.
[28] WANG S Y, WANG X, TAN Z L, et al. Human ESC-derived expandable hepatic organoids enable therapeutic liver repopulation and pathophysiological modeling of alcoholic liver injury[J]. Cell Res, 2019, 29(12): 1009-1026.
[29] HU H L, GEHART H, ARTEGIANI B, et al. Long-term expansion of functional mouse and human hepatocytes as 3D organoids[J]. Cell, 2018, 175(6): 1591-1606.
[30] SHIOTA J, ZAKI N H M, MERCHANT J L, et al. Generation of organoids from mouse extrahepatic bile ducts[J]. J Vis Exp, 2019(146): 10.3791/59544.
[31] RIMLAND C A, TILSON S G, MORELL C M, et al. Regional differences in human biliary tissues and corresponding in vitro-derived organoids[J]. Hepatology, 2021, 73(1): 247-267.
[32] ROOS F J M, WU H Y, WILLEMSE J, et al. Cholangiocyte organoids from human bile retain a local phenotype and can repopulate bile ducts in vitro[J]. Clin Transl Med, 2021, 11(12): e566.